Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719093 | PMC |
| http://dx.doi.org/10.3324/haematol.2021.278761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience.
Platelets
December 2024
Hematology and Transplantation Unit, IRCCS San Gerardo Hospital, Monza, Italy.
Acquired Aplastic Anemia (AAA) is a rare disease involving primary bone marrow failure with consequent pancytopenia. The addition of the synthetic thrombopoietin-receptor agonist eltrombopag (ELT) to standard immunosuppression for the treatment of AAA has led to improvements in hemopoietic outcomes of AAA. Most of the data on the use of ELT for AAA was based on a maximum of 6 months of therapy.
View Article and Find Full Text PDFAdding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients.
Leukemia
November 2024
Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Concurrent Guillain-Barre/acute transverse myelitis overlap syndrome after COVID-19 infection in a patient with ITP: A case report.
Medicine (Baltimore)
November 2024
Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
Article Synopsis
- Patients with chronic immune diseases, like ITP, need to be particularly cautious of GBS/ATM overlap syndrome following a COVID-19 infection.
- A 65-year-old man with ITP developed symptoms like limb weakness and facial paralysis two weeks post-COVID-19 diagnosis and was diagnosed with GBS/ATM overlap syndrome.
- After receiving treatment with intravenous immune globulin and other medications, he showed significant improvement and resumed normal activities, even successfully battling a second COVID-19 infection five months later with milder symptoms.
Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.
Exp Hematol
December 2024
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China. Electronic address:
Article Synopsis
- Severe aplastic anemia (SAA) is a serious condition causing bone marrow failure, and adding the drug avatrombopag (AVA) to standard immunosuppressive therapy (IST) shows promise in improving treatment responses without liver damage.
- A study compared 42 patients receiving AVA + IST with a historical group of 84 patients on IST alone, revealing that those on AVA had significantly higher complete and overall response rates at both 3 and 6 months.
- AVA was well-tolerated with no observed liver toxicity, and better treatment outcomes were noted, especially for those starting ATG treatment within 6 months of disease onset.
Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
Syst Rev
April 2024
Department of Hematology, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Background And Objective: Immunosuppressive therapy (IST) is the first choice for severe aplastic anemia (SAA) patients with hematopoietic stem cell transplantation (HSCT) limitation, and the main factor limiting its efficacy is too few residual hematopoietic stem/progenitor cells (HSPC). Eltrombopag (EPAG), as a small molecule thrombopoietin receptor agonist, can stimulate the proliferation of residual HSPC and restore the bone marrow hematopoietic function of patients. In recent years, many studies have observed the efficacy and safety of IST combined with EPAG in the treatment of SAA, but the results are still controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!